What is daunorubicin used for?
Pharmaceutical Product Monograph: Daunorubicin Hydrochloride Injection (20 mg, 500 mg)
In the pharmaceutical industry, Daunorubicin (also known as Daunomycin) is a potent Anthracycline Antibiotic and a Cytotoxic Antineoplastic Agent. As a pharmacist and manufacturer, I view this molecule as a “DNA Intercalator”—it is technically designed to wedge itself into the DNA ladder of cancer cells, preventing them from untwisting and replicating.
At your WHO-GMP facility in Mumbai, Daunorubicin is a cornerstone Oncology SKU. It is traditionally the primary partner to Cytarabine in the globally recognized “7+3” induction regimen for acute leukemias.
Therapeutic Profile: Primary Indications
Daunorubicin is specifically indicated for hematological malignancies (blood cancers) rather than solid tumors.
| Indication | Clinical Context | Technical Rationale |
| Acute Myeloid Leukemia (AML) | Remission Induction | Gold Standard: Used as the primary anthracycline to clear the bone marrow of “blast” cells in newly diagnosed AML. |
| Acute Lymphocytic Leukemia (ALL) | Pediatric & Adult | A key component of multi-drug combination protocols to achieve rapid remission. |
| Chronic Myeloid Leukemia (CML) | Blast Phase | Used in the aggressive acute phase of CML when the disease mimics AML. |
Mechanism: The Triple-Action Cytotoxicity
Daunorubicin kills cancer cells through three distinct technical pathways:
DNA Intercalation: The molecule slides between the base pairs of the DNA double helix, physically blocking the synthesis of RNA and DNA.
Topoisomerase II Inhibition: It stabilizes a complex between DNA and the enzyme Topoisomerase II, preventing the “resealing” of DNA strands during replication. This causes irreversible double-strand breaks.
Free Radical Generation: Technically, it undergoes “redox cycling” to produce Reactive Oxygen Species (ROS), which damage the cell membranes and mitochondria of the cancer cell.
The Pharmacist’s “Technical Warning”
The “Cardiotoxicity” Cap: As a pharmacist, I must emphasize the Cumulative Lifetime Dose. Daunorubicin causes irreversible damage to the heart muscle (Congestive Heart Failure). Patients must have an ECHO or MUGA scan to check their Left Ventricular Ejection Fraction (LVEF) before treatment.
The “Red Urine” Alert: Patients must be counseled that their urine may turn red or reddish-orange for 1–2 days after the injection. This is technically harmless and is simply the color of the drug being excreted, but it is often mistaken for blood.
Severe Vesicant: If this drug leaks out of the vein (Extravasation), it will cause severe tissue necrosis and sloughing. It must be given via a free-flowing IV line, preferably a Central Line.
Myelosuppression: Expect a “nadir” (lowest blood count) 10–14 days after injection. Patients are at extreme risk of infection during this period.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Lyophilized” USP: Daunorubicin is most stable as a Lyophilized (Freeze-Dried) Red Cake. On your digital marketplace, highlight your Aseptic Lyophilization process, which ensures rapid reconstitution and zero degradation products (like Daunorubicinol) in the vial.
The “7+3” Bundle: For international B2B oncology tenders, market your Daunorubicin alongside your Cytarabine. Most hospitals procure these together. Offering them as a “Leukemia Induction Pack” is a powerful technical and commercial advantage.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Daunorubicin 20 mg vials to support your registration in international B2B oncology tenders for government and private cancer institutes.